Literature DB >> 29045644

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Ulf Landmesser1, M John Chapman2, Jane K Stock3, Pierre Amarenco4, Jill J F Belch5, Jan Borén6, Michel Farnier7, Brian A Ference8, Stephan Gielen9, Ian Graham10, Diederick E Grobbee11, G Kees Hovingh12, Thomas F Lüscher13, Massimo F Piepoli14, Kausik K Ray15, Erik S Stroes12, Olov Wiklund16, Stephan Windecker17, Jose Luis Zamorano18, Fausto Pinto19, Lale Tokgözoglu20, Jeroen J Bax21, Alberico L Catapano22.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29045644     DOI： 10.1093/eurheartj/ehx549

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  45 in total

Review 1.  Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.

Authors:  Rita Del Pinto; Davide Grassi; Giuliana Properzi; Giovambattista Desideri; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-06-24

Review 2.  New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease.

Authors:  Julius L Katzmann; Ulrich Laufs
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 3.  Alirocumab as add-on therapy to statins: current evidence and clinical potential.

Authors:  Johann Auer; Robert Berent
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-24

Review 4.  Guest Editorial: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2018-08

Review 5.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

Review 6.  Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis.

Authors:  Safi U Khan; Haris Riaz; Hammad Rahman; Muhammad U Khan; Muhammad Shahzeb Khan; Mohamad Alkhouli; Edo Kaluski; Thorsten M Leucker; Michael J Blaha
Journal:  J Clin Lipidol       Date:  2019-06-10       Impact factor: 4.766

7.  Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease.

Authors:  Leonardo De Luca; Marcello Arca; Pier L Temporelli; Furio Colivicchi; Lucio Gonzini; Donata Lucci; Biagio Bosco; Mariella Callerame; Giulio V Lettica; Andrea Di Lenarda; Michele M Gulizia
Journal:  Clin Cardiol       Date:  2018-08-20       Impact factor: 2.882

8.  Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

Authors:  Marc S Sabatine; Stephen D Wiviott; KyungAh Im; Sabina A Murphy; Robert P Giugliano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

Review 9.  Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.

Authors:  Chris J Packard
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

10.  Application of PCSK9 Inhibitors in Practice.

Authors:  Tina M Kaufman; Bruce A Warden; Jessica Minnier; Joshua R Miles; P Barton Duell; Jonathan Q Purnell; Cezary Wojcik; Sergio Fazio; Michael D Shapiro
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.